Multiple Myeloma

ClinicalAugust 6, 2026

NCI Trials Mirdametinib and Sirolimus in RAS Mutated Relapsed Refractory Multiple Myeloma

A clinical trial is underway to evaluate the safety and efficacy of mirdametinib and sirolimus in patients with RAS mutated relapsed refractory multiple myeloma.

ClinicalAugust 5, 2026

Phase II Study of Elranatamab in Outpatients with Relapsed/Refractory Multiple Myeloma

The study aims to assess the incidence of cytokine release syndrome during the first treatment cycle of elranatamab in RRMM patients.

ClinicalAugust 5, 2026

Selinexor shows promise in high-risk multiple myeloma with XVRd regimen

The study evaluates the efficacy and safety of the XVRd regimen in newly diagnosed multiple myeloma patients with high-risk factors.

ClinicalAugust 4, 2026

Elranatamab and Iberdomide Combination Study in Relapsed/Refractory Multiple Myeloma Initiated

A clinical trial is underway to evaluate the safety and tolerability of elranatamab combined with iberdomide in patients with relapsed or refractory multiple myeloma.

ClinicalAugust 3, 2026

Study on Digital Support Impact on Multiple Myeloma Patient Quality of Life

A prospective study is underway to evaluate the effectiveness of a personalized web-based platform on the quality of life for multiple myeloma patients.

RegulatoryJuly 31, 2026

FDA Approves Lenalidomide Supplement by Zydus Pharmaceuticals

The FDA has approved a supplemental application for lenalidomide submitted by Zydus Pharmaceuticals.

StrategyJuly 31, 2026

FDA Approves Lenalidomide ANDA217554 Submission by Deva Holding AS

The FDA has approved the ANDA217554 submission for Lenalidomide by Deva Holding AS.

RegulatoryJuly 30, 2026

FDA Accepts Supplemental Application for REVLIMID by Bristol Myers Squibb

The FDA has accepted a supplemental application for REVLIMID (lenalidomide) submitted by Bristol Myers Squibb.

ClinicalJuly 30, 2026

Regeneron initiates study on linvoseltamab for high-risk monoclonal gammopathy

Regeneron Pharmaceuticals is conducting a proof-of-concept study to evaluate linvoseltamab's efficacy in eliminating abnormal plasma cells in patients at risk of multiple myeloma.

StrategyJuly 30, 2026

Cipla's Lenalidomide ANDA213165 Receives AP Status from FDA

Cipla's application for lenalidomide has received an Abbreviated Approval (AP) status from the FDA.

RegulatoryJuly 29, 2026

FDA Accepts Supplemental Application for REVLIMID by Bristol Myers Squibb

The FDA has accepted a supplemental application for REVLIMID (lenalidomide) from Bristol Myers Squibb.

ClinicalJuly 26, 2026

Isatuximab Evaluated in Stem Cell Transplant for Multiple Myeloma and Lymphoma

A clinical trial is investigating the effects of Isatuximab on the immune system during stem cell recovery in multiple myeloma and lymphoma patients.

ClinicalJuly 25, 2026

Study on 18F-Fluciclovine PET/CT for Improved Detection in Multiple Myeloma

A clinical trial is underway to evaluate the efficacy of 18F-fluciclovine PET/CT compared to 18F-FDG in detecting multiple myeloma.

ClinicalJuly 23, 2026

Phase Ib Trial of Teclistamab and Iberdomide in Relapsed/Refractory Multiple Myeloma

A phase Ib trial is underway to evaluate the safety and dosing of iberdomide combined with teclistamab for relapsed or refractory multiple myeloma.

ClinicalJuly 23, 2026

Study on Engineered Dendritic Cell Vaccines for Multiple Myeloma Initiated

A clinical trial is underway to assess the feasibility, safety, and efficacy of engineered dendritic cell vaccines for multiple myeloma.

CompetitiveJuly 23, 2026

AbbVie Initiates Study on Surzetoclax for Relapsed/Refractory Multiple Myeloma

AbbVie is conducting a study to evaluate the safety and efficacy of surzetoclax in combination with other agents for relapsed/refractory multiple myeloma.

ClinicalJuly 22, 2026

JNJ-79635322 Dose Escalation Study in Multiple Myeloma Shows Promising Combinations

The study aims to establish recommended Phase 2 doses for JNJ-79635322 in combination with daratumumab and other agents.

ClinicalJuly 18, 2026

Study Evaluates Cilta-cel and Talquetamab Combinations with Daratumumab in Multiple Myeloma

The study aims to assess treatment response rates and potential cure indicators at 5 years post-induction therapy.

ClinicalJuly 18, 2026

AstraZeneca's AZD0120 Phase I Study in Multiple Myeloma Initiated

AstraZeneca has initiated Phase I study to evaluate the safety and tolerability of AZD0120 in multiple myeloma patients.

RegulatoryJuly 11, 2026

FDA Approves Isatuximab-irfc Subcutaneous Injection for Multiple Myeloma

The FDA has approved isatuximab-irfc for subcutaneous administration in multiple myeloma.

StrategyJuly 10, 2026

Elranatamab shows robust efficacy and favorable safety in relapsed/refractory multiple myeloma

Elranatamab is a bispecific antibody approved for relapsed/refractory multiple myeloma, demonstrating a favorable safety profile and robust efficacy.

ClinicalJuly 8, 2026

Bristol-Myers Squibb Evaluates Pomalidomide Outcomes in Relapsed/Refractory Multiple Myeloma

A retrospective study will assess clinical outcomes of pomalidomide regimens in relapsed/refractory multiple myeloma.

ClinicalJuly 8, 2026

Teclistamab Combination Study in Multiple Myeloma Initiated by Janssen

A new clinical trial is underway to evaluate the safety and tolerability of teclistamab in combination with other anticancer therapies for multiple myeloma.

ClinicalJuly 7, 2026

JNJ-87562761 Phase 2 Study Initiated for Relapsed/Refractory Multiple Myeloma

Janssen is conducting a study to establish the recommended phase 2 dose and assess safety of JNJ-87562761 in relapsed or refractory multiple myeloma patients.

StrategyJuly 7, 2026

Cipla's Lenalidomide ANDA210435 Receives Abbreviated Approval from FDA

Cipla has received an abbreviated approval (AP) for its ANDA210435 application for Lenalidomide.

RegulatoryJuly 7, 2026

FDA Acceptance of Supplemental NDA for REVLIMID by Bristol Myers Squibb

The FDA has accepted a supplemental NDA for REVLIMID (lenalidomide) submitted by Bristol Myers Squibb.

RegulatoryJuly 6, 2026

FDA Approves Supplemental Application for Thalidomide (Thalomid)

The FDA has approved a supplemental application for Thalomid (thalidomide) submitted by Bristol-Myers.

ClinicalJuly 3, 2026

Bristol-Myers Squibb Compares Iberdomide to Lenalidomide in Multiple Myeloma Maintenance Therapy

A clinical trial is underway to evaluate iberdomide maintenance therapy against lenalidomide maintenance following ASCT in NDMM patients.

ClinicalJuly 3, 2026

Genentech initiates study on cevostamab and elranatamab for relapsed/refractory multiple myeloma

Genentech is evaluating the safety and pharmacokinetics of cevostamab in combination with elranatamab for R/R MM.

ClinicalJuly 2, 2026

GSK's Belantamab Mafodotin Study Targets Multiple Myeloma with Renal Impairment

A study is underway to evaluate the safety and pharmacokinetics of belantamab mafodotin in multiple myeloma patients with varying degrees of renal impairment.

ClinicalJuly 1, 2026

Phase III Trial of Ixazomib and Lenalidomide in Solitary Plasmacytoma Post-Radiation

A phase III trial is underway comparing ixazomib citrate, lenalidomide, dexamethasone, and zoledronic acid versus zoledronic acid alone after radiation therapy for solitary plasmacytoma of bone.

ClinicalJune 20, 2026

RBMS1 identified as a key factor in multiple myeloma malignancy and macrophage polarization

RBMS1 enhances PDPK1 mRNA stability, promoting multiple myeloma cell proliferation and M2 macrophage polarization.

ClinicalJune 17, 2026

Pfizer's ELREXFIO Shows Significant PFS Improvement in RRMM Patients

The Phase 3 MagnetisMM-5 trial demonstrated a statistically significant improvement in progression-free survival for ELREXFIO in patients with relapsed or refractory multiple myeloma compared to standard-of-care.

Companies

Assets

Recent signals(33)

NCI Trials Mirdametinib and Sirolimus in RAS Mutated Relapsed Refractory Multiple Myeloma

Phase II Study of Elranatamab in Outpatients with Relapsed/Refractory Multiple Myeloma

Selinexor shows promise in high-risk multiple myeloma with XVRd regimen

Elranatamab and Iberdomide Combination Study in Relapsed/Refractory Multiple Myeloma Initiated

Study on Digital Support Impact on Multiple Myeloma Patient Quality of Life

FDA Approves Lenalidomide Supplement by Zydus Pharmaceuticals

FDA Approves Lenalidomide ANDA217554 Submission by Deva Holding AS

FDA Accepts Supplemental Application for REVLIMID by Bristol Myers Squibb

Regeneron initiates study on linvoseltamab for high-risk monoclonal gammopathy

Cipla's Lenalidomide ANDA213165 Receives AP Status from FDA

FDA Accepts Supplemental Application for REVLIMID by Bristol Myers Squibb

Isatuximab Evaluated in Stem Cell Transplant for Multiple Myeloma and Lymphoma

Study on 18F-Fluciclovine PET/CT for Improved Detection in Multiple Myeloma

Phase Ib Trial of Teclistamab and Iberdomide in Relapsed/Refractory Multiple Myeloma

Study on Engineered Dendritic Cell Vaccines for Multiple Myeloma Initiated

AbbVie Initiates Study on Surzetoclax for Relapsed/Refractory Multiple Myeloma

JNJ-79635322 Dose Escalation Study in Multiple Myeloma Shows Promising Combinations

Study Evaluates Cilta-cel and Talquetamab Combinations with Daratumumab in Multiple Myeloma

AstraZeneca's AZD0120 Phase I Study in Multiple Myeloma Initiated

FDA Approves Isatuximab-irfc Subcutaneous Injection for Multiple Myeloma

Elranatamab shows robust efficacy and favorable safety in relapsed/refractory multiple myeloma

Bristol-Myers Squibb Evaluates Pomalidomide Outcomes in Relapsed/Refractory Multiple Myeloma

Teclistamab Combination Study in Multiple Myeloma Initiated by Janssen

JNJ-87562761 Phase 2 Study Initiated for Relapsed/Refractory Multiple Myeloma

Cipla's Lenalidomide ANDA210435 Receives Abbreviated Approval from FDA

FDA Acceptance of Supplemental NDA for REVLIMID by Bristol Myers Squibb

FDA Approves Supplemental Application for Thalidomide (Thalomid)

Bristol-Myers Squibb Compares Iberdomide to Lenalidomide in Multiple Myeloma Maintenance Therapy

Genentech initiates study on cevostamab and elranatamab for relapsed/refractory multiple myeloma

GSK's Belantamab Mafodotin Study Targets Multiple Myeloma with Renal Impairment

Phase III Trial of Ixazomib and Lenalidomide in Solitary Plasmacytoma Post-Radiation

RBMS1 identified as a key factor in multiple myeloma malignancy and macrophage polarization

Pfizer's ELREXFIO Shows Significant PFS Improvement in RRMM Patients

Upcoming catalysts

Indications

Get signals before the market moves